Skip to main content

Table 2 Overview of pathogen reduction/inactivation technologies compatible with platelet concentrates

From: Bacterial contamination of platelets for transfusion: strategies for prevention

  INTERCEPT™ Blood System for Platelets Mirasol® Pathogen Reduction Technology System THERAFLEX® UV-Platelets
Manufacturer Cerus Corporation Terumo BCT MacoPharma
FDA approval for platelets Yes No No
CE mark approval CE class III CE class IIB CE class IIB
Principle of method UVA illumination in the presence of a photosensitizer Broad-spectrum UV illumination in the presence of a photosensitizer UVC illumination and intense platelet bag agitation
Photosensitizer Amotosalen Riboflavin None
UV wavelength and dose UVA, 320–400 nm, 3 J/cm2 UVB/UVA/UVC (100%/60%/20%), 265–370 nm, 6.2 J/mL UVC, 254 nm, 0.2–0.3 J/cm2
Pathogens targeted Bacteria (Gram-positive and Gram-negative), viruses (enveloped and non-enveloped), parasites Bacteria (Gram-positive and Gram-negative), viruses (enveloped and non-enveloped), parasites Bacteria (Gram-positive and Gram-negative), viruses (enveloped and non-enveloped), parasites
Toxicology testinga Acute toxicology, carcinogenicity, general pharmacology, genotoxicity, phototoxicity, repeated dose, reproductive toxicology (plus others) Acute toxicology, genotoxicity, phototoxicity, repeated dose, reproductive toxicology (plus others) Not applicable (no exogenous photosensitizer)
Bacterial inactivation (log reduction)b
 Gram-positive 3.6 to >6.9 1.9 to 4.8 4.3 to >4.9
 Gram-negative 4.5 to >6.7 2.8 to 5.4 >4.0 to >4.9
Maximum approved storagec 5 and 7 days 7 days 5 days
  1. Abbreviations: CE Conformité Européene (“European Conformity”), FDA US Food and Drug Administration, UV ultraviolet
  2. aSee [43, 44] for additional details
  3. bSee [43, 44] for data on individual bacterial species tested
  4. cDepending on country